Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174869 · ClinicalTrials.gov registry record
A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population
A clinical trial of Mild Cognitive Impairment (MCI) and Mild Alzheimer Disease, sponsored by Indivi.
- Recruiting
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT07174869: Recruiting study of Mild Cognitive Impairment (MCI) and Mild Alzheimer Disease, sponsored by Indivi.
NCT07174869 is a study of Mild Cognitive Impairment (MCI) and Mild Alzheimer Disease that is actively recruiting participants, run by Indivi. The registered enrollment target is 55 participants, below the 157-participant average among 19 other Mild Cognitive Impairment (MCI) trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07174869, a study of Mild Cognitive Impairment (MCI) and Mild Alzheimer Disease, is actively recruiting participants, sponsored by Indivi.
- RECRUITING
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to evaluate the functionality and usability of Indivi mobile application-based cognitive activities in people with mild cognitive impairment/mild Alzheimer's disease (PwMCI/AD) and healthy controls (HC). This application uses a dynamic difficulty adjustment (DDA) system that customizes the level of the cognitive activities to each user. The main questions it aims to answer are: * Does the DDA system reach a stable difficulty level at the same rate for both PwMCI/AD and HC? * Is the stable difficulty level reached by the DDA system different for PwMCI/AD compared to HC? Researchers will also compare cognitive activities results and other aspects of the mobile application's performance to see if the application can validly distinguish between the two groups. Participants will use the Indivi mobile application, with its embedded DDA system, for a 6-week period.
Primary Outcome
Stable difficulty level is defined as no increase in difficulty across 3 consecutive test iterations. Comparison will be made between PwMCI and HC.
Conditions Studied
Study Locations (1)
Massachusetts
- Boston University School of Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-09 |
| Est. Completion | 2026-06 |
What NCT07174869 shows while recruiting
NCT07174869 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 157-participant average among 19 other Mild Cognitive Impairment (MCI) trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Mild Cognitive Impairment (MCI) appearing as the primary indexed condition, and to 0 interventions.
NCT07174869 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07174869 about?
NCT07174869 is a clinical study titled "A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population". The goal of this observational study is to evaluate the functionality and usability of Indivi mobile application-based cognitive activities in people with mild cognitive impairment/mild Alzheimer's disease (PwMCI/AD) and healthy controls (HC). This application uses a dynamic difficulty adjustment (D...
What is the current status of trial NCT07174869?
This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2025-09. Estimated completion is 2026-06.
What conditions does trial NCT07174869 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment (MCI), Mild Alzheimer Disease.
Who is sponsoring clinical trial NCT07174869?
This trial is sponsored by Indivi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174869 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment (MCI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07174869's enrollment target sits among peer trials
55 10th of 19 higher than 10 of 19 other Mild Cognitive Impairment (MCI) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment (MCI) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Music for the Mind Study
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
The "Let's Talk Tech" Tool to Support Decision Making About Technology Use
RECRUITING · NA
-
Project Gnosis: the Neurophysical and Psychosocial Health Outcomes of Tai Chi for Older Adults with Cognitive Concerns or Mild Cognitive Impairment
RECRUITING · NA
-
Working Memory Training in Patients with Mild Cognitive Impairment
RECRUITING · NA
-
Treating Insomnia in Mild Cognitive Impairment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia